$IRTC

Freeman Sean Clinton sold $114K of IRTC

Freeman Sean Clinton (EVP, Strategy & Corp Devt) sold 918 shares of iRhythm Holdings, Inc. (IRTC) at $124.71 ($0.11M total) on 2026-07-02.

Original reporting
SEC EDGAR · Freeman Sean Clinton
Published Jul 6, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale: 918 shares at $124.71 on 2026-07-02, with post-sale holdings of 13,641 shares and no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may monitor for patterns of insider selling, but this single transaction lacks fundamental catalysts.

03

What to watch

Insider sales often reflect liquidity needs, tax planning, or diversification; without additional context (e.g., total insider activity, prior grants, or large-scale selling), signal quality is limited.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-06 after-hours; reflects sale executed 2026-07-02.

Background

The article is a primary-source SEC Form 4 insider transaction for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

IRTC disclosed an EVP Strategy & Corp Development open-market sale of 918 shares at $124.71 on 2026-07-02 via Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is a Form 4 insider transaction (not a guidance/earnings/regulatory event). The disclosed sale size is modest relative to typical market impact, and no new company-specific operational information is provided.

Market effects

No clear sector read-through; this is company-specific insider dealing.

None indicated.

None indicated.

Counterpoint

Absence of a stated 10b5-1 plan could be interpreted as discretionary selling rather than scheduled diversification, but the article provides no motive.

Key entities

  • iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction; EVP sold shares via open-market sale.

  • Freeman Sean Clinton

    EVP, Strategy & Corporate Development; reported open-market sale of 918 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.